SBF2 and breast carcinoma: Through whole-exome sequencing (WES), we identified the association of five rare variants in SET-Binding Factor 2 (SBF2) with an increased risk of TIPN in AA patients in the randomized phase III adjuvant breast cancer trial, ECOG-ACRIN-5103 [21].